24 Results for "

hepatic fatty acid oxidation

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "hepatic fatty acid oxidation" in MCE Product Catalog:

50
50 Publications Verification
Cat. No.: HY-114118
CAS No.: 910463-68-2
Purity:  99.84%
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
50
50 Publications Verification
Cat. No.: HY-114118B
CAS No.: 1997361-85-9
Purity:  99.92%
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
50
50 Publications Verification
Cat. No.: HY-114118A
Purity:  99.92%
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N0712
CAS No.: 104472-68-6
Typhaneoside is an orally active activator of PI3K/Akt/mTOR and farnesoid X receptor. Typhaneoside promotes the activation of AMPK and Caspase-3, induces apoptosis, ferroptosis, autophagy, ROS accumulation, cell cycle arrest at the G2/M phase, and reduces cancer cell viability. Typhaneoside improves glucose and lipid metabolism, alleviates inflammatory responses, oxidative stress and hepatic lipid accumulation, and exerts hepatoprotective effects. Typhaneoside can be used in research related to heart failure after myocardial infarction, acute myeloid leukemia, non-alcoholic fatty liver disease and neurological disorders .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113165A
CAS No.: 6920-31-6
Purity:  ≥98.0%
Isobutyryl-L-carnitine chloride is a biomarker. Isobutyryl-L-carnitine chloride is a product of acyl-CoA dehydrogenases involved in fatty acid β-oxidation, and it buffers the mitochondrial acyl-CoA/CoA ratio, oxidizes branched-chain amino acids, and supports the endogenous antioxidant defense system. Isobutyryl-L-carnitine chloride is a plasma biomarker of hepatic OCT1 transporter inhibition. Isobutyryl-L-carnitine chloride is a urinary biomarker of renal cell carcinoma, and its levels are elevated one year after nephrectomy compared with before nephrectomy. Isobutyryl-L-carnitine chloride can be used in research on renal cell carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-113165
CAS No.: 25518-49-4
Isobutyryl-L-carnitine is a biomarker. Isobutyryl-L-carnitine is a product of acyl-CoA dehydrogenases involved in fatty acid β-oxidation, and it buffers the mitochondrial acyl-CoA/CoA ratio, oxidizes branched-chain amino acids, and supports the endogenous antioxidant defense system. Isobutyryl-L-carnitine is a plasma biomarker of hepatic OCT1 transporter inhibition. Isobutyryl-L-carnitine is a urinary biomarker of renal cell carcinoma, and its levels are elevated one year after nephrectomy compared with before nephrectomy. Isobutyryl-L-carnitine can be used in research on renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-114118CP
CAS No.: 910463-68-2
Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-114118S3
Purity:  96.04%
Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-114118S
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-114118S1
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-139040
CAS No.: 2921-20-2
Purity:  ≥98.0%
Target:  

PPAR

Research Areas:  

Metabolic Disease

2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .
loading...
    loading...
Cat. No.: HY-168049
CAS No.: 2834727-04-5
Target:  

PPAR Akt

Research Areas:  

Metabolic Disease

ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
loading...
    loading...
Cat. No.: HY-113165AS
Isobutyryl-L-carnitine-d3 chloride is the d3-labeled Isobutyryl-L-carnitine chloride (HY-113165A). Isobutyryl-L-carnitine chloride is a biomarker. Isobutyryl-L-carnitine chloride is a product of acyl-CoA dehydrogenases involved in fatty acid β-oxidation, and it buffers the mitochondrial acyl-CoA/CoA ratio, oxidizes branched-chain amino acids, and supports the endogenous antioxidant defense system. Isobutyryl-L-carnitine chloride is a plasma biomarker of hepatic OCT1 transporter inhibition. Isobutyryl-L-carnitine chloride is a urinary biomarker of renal cell carcinoma, and its levels are elevated one year after nephrectomy compared with before nephrectomy. Isobutyryl-L-carnitine chloride can be used in research on renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-123115
CAS No.: 7158-70-5
Synonyms: 5-O-α-D-Glucopyranosyl-D-fructose
Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active Sucrose (HY-B1779) isomer naturally found in pollen and honey. Leucrose promotes phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokinesas (TNFα, and IL-1β), increases M2 macrophage polarization and suppresses DSS (HY-116282C)-induced colitis. Leucrose suppresses hepatic triglyceride accumulation, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation in high-fat diet-induced obese mice. Leucrose is slowly hydrolyzed into glucose and fructose by α-glucosidase and acts as as a sugar substitute in diet .
loading...
    loading...
Cat. No.: HY-179473
CAS No.: 690257-74-0
MK-0626 is a selective, orally active DPP-4 inhibitor with an IC50 of 6.3 nM. MK-0626 increases endothelial nitric oxide synthetase expression. MK-0626 improves neovascularization, attenuates hepatic steatosis, attenuates pancreatic islet injury. MK-0626 can be used in the research of diabetes and non-alcoholic fatty liver disease .
loading...
    loading...
Cat. No.: HY-Y1150
CAS No.: 75-98-9
Synonyms: Trimethylmethanecarboxylic acid; Versatic 5 acid; tert-Pentanoic acid
Target:  

Antibiotic

Research Areas:  

Inflammation/Immunology

Pivalic acid (Trimethylmethanecarboxylic acid) is a carboxylic acid. Pivalic acid induces Carnitine deficiency. Pivalic acid conjugated with Antibiotics, such as Pivmecillinam (HY-B0810) and Pivampicillin (HY-119011), are used in urinary tract infection. Pivalic acid can be used in physical exercise research .
loading...
    loading...
Cat. No.: HY-139040R
CAS No.: 2921-20-2
Synonyms: Tetradecylthioacetic acid (Standard)
Research Areas:  

Metabolic Disease

2-(Tetradecylthio)acetic acid (Standard) is the analytical standard of 2-(Tetradecylthio)acetic acid. This product is intended for research and analytical applications. 2-Tetradecylthio acetic acid is a pan-peroxisome proliferator activated receptor (pan-PPAR) activator. 2-Tetradecylthio acetic acid induces hypolipidemia. 2-Tetradecylthio acetic acid reduces plasma lipids and enhances hepatic fatty acid oxidation in rodents. 2-Tetradecylthio acetic acid increases the expression of genes involved in fatty acid uptake, activation, accumulation, and oxidation .
loading...
    loading...
Cat. No.: HY-113165AR
CAS No.: 6920-31-6
Isobutyryl-L-carnitine chloride (Standard) is the analytical standard of Isobutyryl-L-carnitine chloride (HY-113165A). This product is intended for research and analytical applications. Isobutyryl-L-carnitine chloride is a biomarker. Isobutyryl-L-carnitine chloride is a product of acyl-CoA dehydrogenases involved in fatty acid β-oxidation, and it buffers the mitochondrial acyl-CoA/CoA ratio, oxidizes branched-chain amino acids, and supports the endogenous antioxidant defense system. Isobutyryl-L-carnitine chloride is a plasma biomarker of hepatic OCT1 transporter inhibition. Isobutyryl-L-carnitine chloride is a urinary biomarker of renal cell carcinoma, and its levels are elevated one year after nephrectomy compared with before nephrectomy. Isobutyryl-L-carnitine chloride can be used in research on renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-W700788
Isobutyryl-L-carnitine chloride-d6 is the d6-labeled Isobutyryl-L-carnitine chloride (HY-113165A). Isobutyryl-L-carnitine chloride is a biomarker. Isobutyryl-L-carnitine chloride is a product of acyl-CoA dehydrogenases involved in fatty acid β-oxidation, and it buffers the mitochondrial acyl-CoA/CoA ratio, oxidizes branched-chain amino acids, and supports the endogenous antioxidant defense system. Isobutyryl-L-carnitine chloride is a plasma biomarker of hepatic OCT1 transporter inhibition. Isobutyryl-L-carnitine chloride is a urinary biomarker of renal cell carcinoma, and its levels are elevated one year after nephrectomy compared with before nephrectomy. Isobutyryl-L-carnitine chloride can be used in research on renal cell carcinoma .
loading...
    loading...
Cat. No.: HY-165175
CAS No.: 25518-51-8
Target:  

Drug Derivative

Research Areas:  

Metabolic Disease

(+)-Decanoylcarnitine is an (S)-acylcarnitine derivative and a potent inhibitor of carnitine-acylcarnitine translocase, with an IC50 of 5 μM. (+)-Decanoylcarnitine acts as a competitive inhibitor of long-chain acylcarnitine transferase and (-)-carnitine palmityltransferase. (+)-Decanoylcarnitine blocks hepatic fatty acid oxidation, ketogenesis, oleate-induced activation of gluconeogenesis, as well as associated changes in acetyl-CoA, citrate, redox pair ratios, flavins and pyridine nucleotides. (+)-Decanoylcarnitine reverses ketosis in vivo, enhances insulin-mediated hypoglycemic effects in anesthetized animals, and reduces plasma ketone body levels when used in combination with insulin. (+)-Decanoylcarnitine can be used in studies related to diabetic ketoacidosis .
loading...
    loading...